Cargando…
Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects
AIMS: SD‐1077, a selectively deuterated precursor of dopamine (DA) structurally related to L‐3,4‐dihydroxyphenylalanine (L‐DOPA), is under development for treatment of motor symptoms of Parkinson's disease. Preclinical models have shown slower metabolism of central deuterated DA. The present st...
Autores principales: | Schneider, Frank, Erisson, Lavi, Beygi, Hooman, Bradbury, Margaret, Cohen‐Barak, Orit, Grachev, Igor D., Guzy, Serge, Loupe, Pippa S., Levi, Micha, McDonald, Mirna, Savola, Juha‐Matti, Papapetropoulos, Spyros, Tracewell, William G., Velinova, Maria, Spiegelstein, Ofer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138493/ https://www.ncbi.nlm.nih.gov/pubmed/29959802 http://dx.doi.org/10.1111/bcp.13702 |
Ejemplares similares
-
Dose-dependent L-dopa/carbidopa-induced hyponatremia presenting with hiccups
por: Shihabudheen, P., et al.
Publicado: (2020) -
l‐Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior
por: Valldeoriola, Francesc, et al.
Publicado: (2017) -
L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study
por: Stocchi, Fabrizio, et al.
Publicado: (2015) -
L-DOPA
por: Hornykiewicz, Oleh
Publicado: (2017) -
Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation
por: Yi, Zhan-Miao, et al.
Publicado: (2018)